Orlistat: its current status as an anti-obesity drug
- 18 March 2002
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 440 (2-3) , 109-117
- https://doi.org/10.1016/s0014-2999(02)01422-x
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Drug treatment for obesityBMJ, 2001
- Fat digestion modulates gastrointestinal sensations induced by gastric distention and duodenal lipid in humansGastroenterology, 2001
- Treatment of obesity: need to focus on high risk abdominally obese patientsBMJ, 2001
- Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitorGut, 2000
- Orlistat in the treatment of obesityExpert Opinion on Pharmacotherapy, 2000
- One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitorInternational Journal of Obesity, 2000
- Orlistat in the Long-term Treatment of Obesity in Primary Care SettingsArchives of Family Medicine, 2000
- Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With OrlistatJAMA, 1999
- Influence of orlistat on the regulation of gallbladder contraction in manDigestive Diseases and Sciences, 1996
- Diabetes Intervention Study: Multi-Intervention Trial in Newly Diagnosed NIDDMDiabetes Care, 1991